20/20 Biolabs entered into a Standstill Agreement with Streeterville Capital to temporarily limit conversions of Series E convertible preferred stock. For 120 days from July 16, 2026, Streeterville will not convert shares unless the common stock trades at least 10% above Nasdaq Rule 5635's Minimum Price, with the standstill ending upon any breach or event of default. The Series E was part of a previously disclosed up to $40 million financing, and the standstill is intended to support market stability during the company's compliance efforts.
Agreement details:
- Agreement type: Standstill Agreement on Series E preferred stock conversions
- Counterparty: Streeterville Capital
- Signed / Effective: Jul 16 2026 / Jul 16 2026
- Duration / Termination: 120 days
- Reason: Support stock stability during Nasdaq compliance efforts
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.